Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study

Abstract

Drug survival is a real-life reflection of drug per-formance in routine medical practice and measures thepatient’s persistence under a given treatment. Survival of sys-temic treatment of atopic dermatitis (AD) in routine clinicalpractice has been evaluated in previous analyses.1–3Recently,dupilumab, a fully human monoclonal antibody that targetsthe interleukin-4 receptor a, has been approved for the treat-ment of moderate-to-severe AD. Although its efficacy andeffectiveness have been reported in previous clinical trials4andreal-world evidence publications,5,6the drug survival analysesof dupilumab have, to date, been limite